Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca PLC    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
01/19/2021 01/20/2021 01/21/2021 01/22/2021 01/25/2021 Date
7722(c) 7645(c) 7650(c) 7777(c) 7897 Last
2 530 444 1 950 270 2 126 404 2 462 698 2 636 978 Volume
+0.78% -1.00% +0.07% +1.66% +1.54% Change
More quotes
Financials (USD)
Sales 2020 26 404 M - -
Net income 2020 2 955 M - -
Net Debt 2020 13 238 M - -
P/E ratio 2020 42,5x
Yield 2020 2,65%
Sales 2021 30 409 M - -
Net income 2021 4 577 M - -
Net Debt 2021 11 668 M - -
P/E ratio 2021 29,8x
Yield 2021 2,69%
Capitalization 140 B 139 B -
EV / Sales 2020 5,79x
EV / Sales 2021 4,98x
Nbr of Employees 70 600
Free-Float 95,7%
More Financials
Company
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by treatment area as follows: - oncology (36.8%); - respiratory diseases (22.9%); - cardiovascular, renal and metabolic diseases (18.6%); - other (21.7%): inflammatory and autoimmune diseases, neurological diseases, gastrointestinal and infectious diseases. Net sales are distributed geographically as follows: the United... 
Sector
Pharmaceuticals
Calendar
01/28Presentation
More about the company
Notations Surperformance© of AstraZeneca PLC
Trading Rating : Investor Rating :
More Ratings
All news about ASTRAZENECA PLC
05:31pASTRAZENECA : EU Calls AstraZeneca Response to Vaccine Delays Unsatisfactory
DJ
04:42pASTRAZENECA : EU says AstraZeneca's explanation of decision to slow COVID-19 vac..
RE
04:07pTHE LATEST : Moderna will test booster dose for virus variant
AQ
03:24pTech Stocks Add to Last Week's Gains
DJ
03:06pEXCLUSIVE : Pfizer wants India to order COVID-19 vaccine before pursuing approva..
RE
02:48pWALL STREET STOCK EXCHANGE : Stocks Open Mixed Amid Renewed Tech Surge
DJ
02:27pStock Futures Diverge Amid Renewed Tech Surge
DJ
12:49pASTRAZENECA : Says Leukemia Drug Calquence Met Endpoints in Trial
MT
12:29pMerck ends COVID vaccine program, cites inferior immune responses
RE
12:23pEU to require advance registration of COVID-19 vaccine exports
RE
11:59aMerck Scraps Covid-19 Vaccine Candidates
DJ
11:57aBioNTech-Pfizer COVID-19 Shot Gains Australian Approval
MT
11:49aAstraZeneca's COVID-19 Vaccine Gains Approval in Bahrain
MT
11:45aMerck ends COVID vaccine program, cites inferior immune responses
RE
11:43aMARKET CHATTER : EU to Meet With AstraZeneca to Seek Clarification on COVID-19 V..
MT
More news
News in other languages on ASTRAZENECA PLC
01:04pFast vier von fünf über 80-Jährigen in Großbritannien geimpft
12:55pUN-Chef warnt vor Corona-Mutation - Chinas Parteichef vor Spaltung
12:35pSTREIT UM CORONA-IMPFSTOFF : EU will Erfassung der Exporte
12:34pUN-Chef warnt vor Corona-Mutation - Impfungen weltweit beschleunigen
12:03pCORONA-BLOG/EU : Lieferverzögerungen bei Astrazeneca "nicht akzeptabel"
More news
Analyst Recommendations on ASTRAZENECA PLC
More recommendations
Stock Trading Strategies
ASTRAZENECA PLC - 01/18
The underlying trend is in force again
BUY
More Stock Trading Analysis
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | AZN | GB0009895292 | MarketScreener
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 25
Average target price 126,47 $
Last Close Price 106,39 $
Spread / Highest target 46,7%
Spread / Average Target 18,9%
Spread / Lowest Target -15,2%
EPS Revisions
Managers and Directors
NameTitle
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA PLC6.19%139 483
JOHNSON & JOHNSON3.92%430 552
ROCHE HOLDING AG3.06%308 615
NOVARTIS AG2.73%220 726
MERCK & CO., INC.-1.00%204 882
PFIZER INC.-0.71%203 159